{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:11Z","timestamp":1791414191844,"version":"4.3.3"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Plazomicin is a next-generation aminoglycoside that is not affected by most clinically relevant aminoglycoside-modifying enzymes. The\n            <jats:italic>in vitro<\/jats:italic>\n            activities of plazomicin and comparator antimicrobials were evaluated against a collection of 5,015 bacterial isolates obtained from patients in Canadian hospitals between January 2011 and October 2012. Susceptibility testing was performed using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method, with MICs interpreted according to CLSI breakpoints, when available. Plazomicin demonstrated potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against members of the family\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            , with all species except\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Proteus mirabilis<\/jats:named-content>\n            having an MIC\n            <jats:sub>90<\/jats:sub>\n            of \u22641 \u03bcg\/ml. Plazomicin was active against aminoglycoside-nonsusceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            , with MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            values identical to those for aminoglycoside-susceptible isolates. Furthermore, plazomicin demonstrated equivalent activities versus extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">E. coli<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            , with 90% of the isolates inhibited by an MIC of \u22641 \u03bcg\/ml. The MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            values for plazomicin against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            were 4 \u03bcg\/ml and 16 \u03bcg\/ml, respectively, compared with 4 \u03bcg\/ml and 8 \u03bcg\/ml, respectively, for amikacin. Plazomicin had an MIC\n            <jats:sub>50<\/jats:sub>\n            of 8 \u03bcg\/ml and an MIC\n            <jats:sub>90<\/jats:sub>\n            of 32 \u03bcg\/ml versus 64 multidrug-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n            isolates. Plazomicin was active against methicillin-susceptible and methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            , with both having MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            values of 0.5 \u03bcg\/ml and 1 \u03bcg\/ml, respectively. In summary, plazomicin demonstrated potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against a diverse collection of Gram-negative bacilli and Gram-positive cocci obtained over a large geographic area. These data support further evaluation of plazomicin in the clinical setting.\n          <\/jats:p>","DOI":"10.1128\/aac.02744-13","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T05:16:41Z","timestamp":1392787001000},"page":"2554-2563","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":104,"title":["<i>In Vitro<\/i>\n            Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012"],"prefix":"10.1128","volume":"58","author":[{"given":"A.","family":"Walkty","sequence":"first","affiliation":[{"name":"Departments of Medicine and Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada"},{"name":"Department of Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Denisuik","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Hoban","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Zhanel","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt027"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2080"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/671740"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70190-7"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.10.028"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm318"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/648451"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/657135"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00207-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.806486"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/518605"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.25"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_1.S46"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq108"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00572-10"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq278"},{"key":"e_1_3_2_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u20147th ed","author":"Clinical and Laboratory Standards Institute","year":"2006","unstructured":"Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u20147th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000015"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-09"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq408"},{"key":"e_1_3_2_24_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Georgescu C","year":"2009","unstructured":"GeorgescuCMartinDABratuSQualeJLandmanD. 2009. Activity of ACHN-490, a novel neoglycoside antibiotic, against contemporary Gram-negative clinical isolates from Brooklyn, NY hospitals, abstr F1-842. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA."},{"key":"e_1_3_2_25_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Biedenbach DJ","year":"2009","unstructured":"BiedenbachDJJonesRNArmstrongESAggenJBMillerGH. 2009. Activity of ACHN-490 against complicated urinary tract infection (cUTI) pathogens from the United States and Europe, abstr F1-843. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq459"},{"key":"e_1_3_2_28_2","volume-title":"Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother.","author":"Riddle V","year":"2012","unstructured":"RiddleVCebrikDArmstrongECassRClobesTHillanK. 2012. Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), abstr L2-2118a. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.016"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02744-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02744-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:39:25Z","timestamp":1645483165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02744-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1128\/AAC.02744-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02744-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"2013-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}